Clinical Trial Update: A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil

View source ↗

Summary

A real-world study in Brazil evaluates demographic, clinical characteristics and outcomes of previously untreated extensive-stage small cell lung cancer patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Durvalumab (durvalumab)
• Etoposide (Etoposide)

Snippet

Sponsor: AstraZeneca | Conditions: Extensive-stage Small-cell Lung Cancer | Status: ACTIVE_NOT_RECRUITING